A study in BMJ Oncology suggests MMR-D/MSI-H urothelial cancer may confer high sensitivity to immunotherapy. This could spare patients the morbidity of radical surgery and the toxicities of chemotherapy.

Andrea Apolo, M.D. Elias Chandran, MBBS Giovanni Maria Iannantuono

bmjoncology.bmj.com/content/3/1/e0…

'Only 10-20% of health is attributable to healthcare...most doctors are downstream...trained to treat the sick, fix the broken, and ease suffering when we can’t cure. It’s the government’s job to tackle the wider causes of ill health.' Dr Helen Salisbury

bmj.com/content/385/bm…

Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019. This article got lots of attention in our first year of publishing 👇
bit.ly/49GPCVE #Oncology #BMJOncology

What is the hardest thing in oncology? Telling a patient and their family, “enough” when the potential for harm is high and the benefit yield is low. JAMA Oncology jamanetwork.com/journals/jamao…

➡️➡️➡️A newest meta-analysis for ICI-based regimens in patients with metastatic renal cell carcinoma➡️➡️➡️

✅PFS and OS are statistically increased in mRCC with ICI combination treatment by 32% and 15%

🎯Undoubtedly, ICI-based combinations are the standard in 1st line treatment…

In this study in JAMA Oncology , a new 18-gene prostate cancer test had higher diagnostic accuracy for high-grade prostate cancer relative to existing biomarker tests.

Clinically, use of this test would have meaningfully reduced unnecessary biopsies performed while maintaining…

A short video on the most important things you need to know about surrogate endpoints in oncology.

youtu.be/CTf8iOo51sY?si…

Adjuvant pembrolizumab was associated with a significant and clinically meaningful improvement in overall survival, as compared with placebo, among participants with clear-cell renal-cell carcinoma at increased risk for recurrence after surgery. nejm.org/doi/full/10.10…

Cancer drugs are increasingly approved with no evidence of improved overall survival or quality of life. The shift towards alternative endpoints and small effect sizes needs to be carefully balanced against the harms of therapy to patients.

Bishal Gyawali

thelancet.com/journals/lanon…

A CRISPR-based gene editing technology eliminated vaso-occlusive crises in 97% of patients with sickle cell disease in a landmark trial published in NEJM. nejm.org/doi/full/10.10…

Cancer drugs are increasingly approved with no evidence of improved overall survival or quality of life. The shift towards alternative endpoints and small effect sizes needs to be carefully balanced against the harms of therapy to patients.

Bishal Gyawali

thelancet.com/journals/lanon…

US cancer guidelines do not always inform clinicians that drugs granted accelerated approval failed to show clinical benefit in confirmatory trials.

Maryam Mooghali, MD, MSc Joseph Ross Reshma Ramachandran Joshua D. Wallach BMJMedicine

bmjmedicine.bmj.com/content/3/1/e0…

How are women doing as cancer researchers worldwide? ✅ our paper just published.women are cited less than men & publish in journals with less impact. Women in HIC are not necessarily doing better than women in LMIC. ⁦Miriam Mutebi ⁦BMJ Oncology⁩ . bmjoncology.bmj.com/content/3/1/e0…

'Gender parity for cancer research authorship is not only a matter of fairness and equality but also essential for advancing scientific knowledge....we still have a lot of work to do'

Kristina Jenei

bmjoncology.bmj.com/content/3/1/e0…

Early Phase Clinical Trials in LMICs: necessity or superfluous?
youtu.be/b36ALHc3vuk

Just out! Sex and authorship in global cancer research
led by the amazing amazing Dr ⁦Miriam Mutebi⁩

▶️Females were more likely to publish in lower impact journals and were less likely to be cited compared to males.

Stay tuned for more … bmjoncology.bmj.com/content/3/1/e0…

An important article was published today that everyone should read about the persisting gaps in female authorship in oncology worldwide. Miriam Mutebi Ophira Ginsburg Richard Sullivan BMJ Oncology

Article: bmjoncology.bmj.com/content/3/1/e0…

My editorial:
bmjoncology.bmj.com/content/3/1/e0…

This recent study in BMJ Oncology found that there may be confounding in the overall survival estimates of phase III oncology trials because of differences in post-progression therapies. bmjoncology.bmj.com/content/3/1/e0…

Ethan Ludmir MD Alexander Sherry and colleagues

Extended follow up of an RCT in NEJM found that adjuvant immunotherapy improves overall survival for renal cell carcinoma. But there were many significant adverse events. nejm.org/doi/full/10.10…

We’ve had readers from 175 countries 🌍 This month we’re celebrating one year of BMJ Oncology 🥳 Read our most popular content: bit.ly/48GReNH
#Oncology #BMJOncology